losartan has been researched along with Ambulation Difficulty in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Excerpt | Relevance | Reference |
---|---|---|
"The Enabling Reduction of Low-grade Inflammation in Seniors (ENRGISE) Pilot Study is a multicenter randomized clinical trial examining the feasibility of testing whether omega-3 fish oil (ω-3) and the angiotensin receptor blocker losartan alone or in combination can reduce inflammation and improve walking speed in older adults with mobility impairment." | 5.30 | The Enabling Reduction of Low-Grade Inflammation in Seniors (ENRGISE) Pilot Study: Screening Methods and Recruitment Results. ( Ambrosius, WT; Anton, SD; Cauley, JA; Domanchuk, K; Fielding, RA; Kennedy, K; Kritchevsky, SB; Lovato, L; Manini, TM; McDermott, MM; Newman, AB; Pahor, M; Stowe, CL; Talton, J; Walkup, M, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Manini, TM | 3 |
Anton, SD | 3 |
Beavers, DP | 2 |
Cauley, JA | 3 |
Espeland, MA | 1 |
Fielding, RA | 3 |
Kritchevsky, SB | 3 |
Leeuwenburgh, C | 2 |
Lewis, KH | 2 |
Liu, C | 1 |
McDermott, MM | 3 |
Miller, ME | 2 |
Tracy, RP | 2 |
Walston, JD | 1 |
Radziszewska, B | 2 |
Lu, J | 2 |
Stowe, C | 1 |
Wu, S | 1 |
Newman, AB | 3 |
Ambrosius, WT | 3 |
Pahor, M | 3 |
Lovato, L | 1 |
Talton, J | 1 |
Domanchuk, K | 1 |
Kennedy, K | 1 |
Stowe, CL | 2 |
Walkup, M | 1 |
Liu, CK | 1 |
Lovato, LC | 1 |
Walkup, MP | 1 |
Wu, SS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study[NCT02676466] | Phase 2 | 289 participants (Actual) | Interventional | 2016-04-26 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Changes in the Interleukin-6 Level Between the Groups (NCT02676466)
Timeframe: Changes from baseline to month 12
Intervention | pg/ml (Mean) |
---|---|
Fish Oil Active | 0 |
Fish Oil Placebo | -0.1 |
Losartan Active | -0.6 |
Losartan Placebo | 3.8 |
Fish Oil Active + Losartan Active | -0.3 |
Fish Oil Active + Losartan Placebo | -0.2 |
Fish Oil Placebo + Losartan Active | -1.4 |
Fish Oil Placebo + Losartan Placebo | -1.0 |
The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles. Scoring will be taken from the best results of 3 trials. Males scores range from 88 pounds as very poor to 141 pounds as excellent with an average of 105-113 pounds. Females scores range from 44 pounds as very poor to 84 pounds as excellent with an average of 57-65 pounds. (NCT02676466)
Timeframe: 12 months
Intervention | pounds (Mean) |
---|---|
Fish Oil Active | 24.8 |
Fish Oil Placebo | 25.3 |
Losartan Active | 25.9 |
Losartan Placebo | 27.5 |
Fish Oil Active + Losartan Active | 22.4 |
Fish Oil Active + Losartan Placebo | 19.8 |
Fish Oil Placebo + Losartan Active | 27.6 |
Fish Oil Placebo + Losartan Placebo | 23.6 |
Frailty will be characterized with Fried criteria developed by Fried et al. that employ self-reported exhaustion, unintentional weight loss, low energy expenditure, slow gait speed, and weak grip strength. Those with >3 of the 5 factors are judged to be frail, those with 1 or 2 factors as pre-frail, and those with no factors as non-frail. (NCT02676466)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Fish Oil Active | 15 |
Fish Oil Placebo | 3 |
Losartan Active | 4 |
Losartan Placebo | 1 |
Fish Oil Active + Losartan Active | 3 |
Fish Oil Active + Losartan Placebo | 3 |
Fish Oil Placebo + Losartan Active | 1 |
Fish Oil Placebo + Losartan Placebo | 1 |
The 400 meter walk test at usual pace is used to evaluate major mobility disability (MMD), defined as the inability to walk ¼ mile or 400 meters. (NCT02676466)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Fish Oil Active | 20 |
Fish Oil Placebo | 5 |
Losartan Active | 4 |
Losartan Placebo | 15 |
Fish Oil Active + Losartan Active | 4 |
Fish Oil Active + Losartan Placebo | 3 |
Fish Oil Placebo + Losartan Active | 7 |
Fish Oil Placebo + Losartan Placebo | 3 |
Peak torque was measured at a rotational speed of 60 degrees per second using a commercially-available Isokinetic Dynamometer (Biodex). Torque was measured during maximal knee extension and flexion reported in Newton Meters. (NCT02676466)
Timeframe: month 12
Intervention | Newton meters (Mean) |
---|---|
Fish Oil Active | 81.3 |
Fish Oil Placebo | 77.7 |
Losartan Active | 87.6 |
Losartan Placebo | 78.6 |
Fish Oil Active + Losartan Active | 85.3 |
Fish Oil Active + Losartan Placebo | 76.6 |
Fish Oil Placebo + Losartan Active | 84.0 |
Fish Oil Placebo + Losartan Placebo | 86.1 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Range: 0-100. A lower score indicates more disability, i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02676466)
Timeframe: month 12
Intervention | score on a scale (Mean) |
---|---|
Fish Oil Active | 41.9 |
Fish Oil Placebo | 42.6 |
Losartan Active | 41.8 |
Losartan Placebo | 41.3 |
Fish Oil Active + Losartan Active | 41.9 |
Fish Oil Active + Losartan Placebo | 42.7 |
Fish Oil Placebo + Losartan Active | 46.6 |
Fish Oil Placebo + Losartan Placebo | 47.9 |
A low score on the SPPB based on 4 m walk, balance & chair stands tests is a risk factor for disability, institutionalization, morbidity and mortality in initially non-disabled older persons. The summary score and components of the SPPB have good reliability (ICCs range from 0.88 to 0.92). Higher scores are better. Range 0-12. (NCT02676466)
Timeframe: 12 months
Intervention | units on a scale (Mean) |
---|---|
Fish Oil Active | 8.6 |
Fish Oil Placebo | 8.1 |
Losartan Active | 8.2 |
Losartan Placebo | 8.4 |
Fish Oil Active + Losartan Active | 8.6 |
Fish Oil Active + Losartan Placebo | 7.3 |
Fish Oil Placebo + Losartan Active | 8.5 |
Fish Oil Placebo + Losartan Placebo | 9.1 |
3 trials available for losartan and Ambulation Difficulty
Article | Year |
---|---|
ENabling Reduction of Low-grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design.
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Inflammat | 2017 |
The Enabling Reduction of Low-Grade Inflammation in Seniors (ENRGISE) Pilot Study: Screening Methods and Recruitment Results.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Fatty Acids, Omega-3; Feasibility Studies; Female; H | 2019 |
Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fatty Acids, | 2019 |